Skip to main content

Immune Checkpoints Beyond PD-1

Edited by Ana Carrizosa Anderson and Dario Vignali

Inspired by the SITC 2018 session “Immune Checkpoints – Beyond PD-1,” JITC continues the impetus of recognizing a widening range of checkpoint targets that are advancing the field forward. Comprised of several authoritative reviews of checkpoints beyond PD-1, this series promotes the tremendous research that is opening new pathways for treating patients with cancer.

  1. The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now ...

    Authors: Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg and Eric Vivier
    Citation: Journal for ImmunoTherapy of Cancer 2019 7:263